Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus and Haemophilus Influenzae Type b (DTPa-IPV/Hib) Conjugate Vaccine

NCT02858440 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02858440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02858440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus and Haemophilus Influenzae Type b (DTPa-IPV/Hib) Conjugate Vaccine
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
September 13, 2016
Completion date
November 13, 2018
Enrollment
235 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diphtheria, haemophilus influenzae type b, hepatitis b, pertussis, tetanus